When people think about vaccine innovation, they often imagine new virus discoveries or advances in antigen design. Yet one of the most critical challenges lies much earlier in the process: producing enough virus consistently to support real-world vaccine manufacturing. For animal and aquaculture vaccines, limitations at this stage can slow development from weeks to months, raise costs, and constrain supply during disease outbreaks. 

To address this often-overlooked bottleneck, researchers at the National Pingtung University of Science & Technology have developed a non-genetically modified cell engineering approach that rethinks how viruses are grown for animal vaccines. In this context, non-genetically modified means that a cell’s DNA is not deliberately altered in the laboratory, an important distinction that helps reduce regulatory complexity while maintaining industrial-level performance. 

The approach is similar to a simple, practical metaphor. Instead of redesigning the factory, the researchers focus on auditing the workers and building the right workplace. Thousands of individual cells are screened to identify those that naturally support virus growth most efficiently. These high-performing cells are then placed in carefully controlled environments, supplied with optimized nutrients and stable conditions, and continuously monitored so they can perform consistently over time. 

Using this strategy, ordinary cells become high-efficiency virus producers, capable of generating millions to tens of millions of virus particles per production cycle: levels typically required for industrial vaccine manufacturing. The method has been demonstrated across diseases affecting pigs, poultry, fish, and the dengue virus, showing flexibility beyond a single pathogen or animal species. 

Beyond efficiency, the innovation brings meaningful ethical benefits. By growing viruses in stable, well-characterized cell lines, the approach reduces reliance on live animals for virus propagation, a practice still used in some vaccine development workflows. This approach allows vaccine research to progress without sacrificing animals, while also improving consistency and repeatability between production batches. 

Cost and scalability are also addressed. Many of the selected cells can grow without animal serum, a component that often accounts for 30–50% of cell culture costs. They can also be expanded in large, free-floating batches suitable for bioreactors holding hundreds to thousands of liters, making the transition from laboratory research to manufacturing more practical and affordable. 

(Newswise/HG)